Fair Value Calculator Fair Value Calculator
EN DE

3390 (3390) Fair Value & Analysis

Healthcare · Market cap HK$208M

3 3390 3390 · HK
PriceHK$0.2330
Fair ValueHK$0.3800
Upside+63.1%
Quality45/100
Watch 3390 for free — get notified when fair value or trend changes. Watch for free
Evidence: High Range HK$0.3100 – HK$0.4600

Fair value as of: Jul 2, 2026

From 26 valuation models · updated today

Share price −10.4% over the past month.

Price vs Fair Value (12 months)

HK$0.3900 HK$0.2330 Fair Value HK$0.3800 Jun 2025 Jul 2026

12‑month range HK$0.2330 – HK$0.3900 · fair‑value band HK$0.3100 – HK$0.4600 · the HK$0.2330 price screens below the HK$0.3800 fair value. As of Jul 2, 2026.

✦ Which stocks are undervalued right now? Check free Discover now →

Analysis

3390 (3390) currently trades at HK$0.2330, while our model-based Fair Value estimate is HK$0.3800 — implying the stock looks roughly 63.1% undervalued today. We read business quality at 45/100 (below-average quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.

Over the trailing twelve months, 3390 generated revenue of HK$1.1B at a net margin of 1.4%. Revenue grew 33.0% year over year. It earns a return on equity of 3.0%. Net debt stands at HK$358M. Fundamentals as of Jul 2, 2026

Key figures & financial health

Revenue (TTM) HK$1.1B
Revenue growth (YoY) +33.0%
Net margin 1.4%
Return on equity 3.0%
Free cash flow HK$96.5M FY2025
P/E ratio 11.7
More key figures
Operating margin 6.3%
EPS (TTM) HK$-0.0100
EPS growth (YoY) -75.4%
Net debt HK$358M FY2025

Figures from reported company fundamentals (EODHD) · as of Jul 2, 2026. TTM = trailing twelve months.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

3390 reported revenue of HK$1.1B in FY2025 versus HK$889M in FY2021, a compound +5.4%/yr. Reported net income was HK$15.7M in FY2025.

Revenue +5.4%/yr
FY21 HK$889M
FY22 HK$1.2B
FY23 HK$1.2B
FY24 HK$876M
FY25 HK$1.1B
Net income
FY21 −HK$18.8M
FY22 HK$43.8M
FY23 HK$297M
FY24 HK$3.2M
FY25 HK$15.7M

Is 3390 fairly valued? → Check now

Similar stocks

6 more Pharmaceutical Retailers stocks, each showing price versus our Fair Value estimate (as of Jul 2, 2026).

Stock Price Fair Value vs Fair Value
JD Health International Inc JDHIY $4.55 $8.78 +93%
6618 6618 HK$34.16 HK$33.08 -3%
Alibaba Health Information Technology Limited ALBBY $8.27 $6.61 -20%
0241 0241 HK$3.08 HK$2.04 -34%
Raia Drogasil S.A RADL3 R$17.76 R$14.97 -16%
Yifeng Pharmacy Chain Co 603939 ¥19.75 ¥40.59 +106%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued Blue-Chip StocksUndervalued Small-Cap Stocks

Frequently asked questions

Is 3390 (3390) undervalued?
As of Jul 2, 2026, our model estimates a fair value of HK$0.3800 versus a price of HK$0.2330 — about +63% (undervalued). Model-based estimate, not financial advice.
What is the fair value of 3390?
Our model-based fair value for 3390 is HK$0.3800 (as of Jul 2, 2026), built from audited fundamentals. The current price is HK$0.2330.
What is the quality score of 3390?
3390 has a Quality Score of 45/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.
What is the revenue of 3390 (3390)?
3390 reported trailing-twelve-month revenue of about HK$1.1B (latest available figure, as of Jul 2, 2026).
What is the net profit margin of 3390?
The net profit margin of 3390 is about 1.4%, meaning it keeps roughly 1.4% of revenue as net income. Based on the latest reported figures.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.